Big Money Sentiment increased to 1.19 in 2018 Q4. It has change of 0.15, from 2018Q3’s 1.04. The ratio improved due to Medifast, Inc. positioning: 44 sold and 61 reduced. 46 funds bought holdings and 79 increased holdings. Investors holded 10.37 million in 2018Q3 but now own 11.30 million shares or 9.02% more.
12 West Cap Mgmt Ltd Partnership holds 2% of its capital in Medifast, Inc. (NYSE:MED) for 155,341 shs. Highstreet Asset Inc owns 15 shs. Bridgeway Cap Mngmt Incorporated, a Texas-based fund reported 3,500 shs. Prudential Fin Inc invested in 0.02% or 96,907 shs. Jane Street Group Ltd Llc invested in 0% or 1,771 shs. Dupont holds 2,725 shs. Envestnet Asset Mgmt holds 2,656 shs. Hsbc Public Ltd Co has 0% invested in Medifast, Inc. (NYSE:MED) for 6,302 shs. Alliancebernstein Limited Partnership invested in 33,560 shs. Loeb Prtn Corp, New York-based fund reported 200 shs. Cambridge Invest Advisors holds 7,095 shs or 0.01% of its capital. 74,470 were accumulated by Charles Schwab Invest Management. Public Sector Pension Inv Board reported 10,522 shs. 166,518 are held by Geode Capital Management Lc. Virginia Retirement Et Al has 6,400 shs for 0.01% of their capital.
Medifast, Inc. registered $272,200 net activity with 1 insider purchase and 2 sales since November 8, 2018. On Thursday, November 8 Chard Daniel R had bought 975 shs worth $149,448.
On May, 2. Investors wait Medifast, Inc. (NYSE:MED) to reveal its quarterly earnings, Zacks reports. EPS of $1.52 is 50.50 % up from 2018’s $1.01 EPS. In case of $1.52 EPS MED’s profit could hit $18.04M. Wall Street now predicts 16.92 % EPS growth despite Medifast, Inc. last quarter’s EPS of $1.30. The stock increased 1.74% or $2.28 during the last trading session, touching $133.38.Medifast, Inc. has volume of 191,924 shares. Since April 8, 2018 MED has risen 103.27% and is uptrending. The stock outperformed the S&P500 by 98.90%.
Medifast, Inc. (NYSE:MED) Ratings Coverage
A total of 2 analysts rate Medifast (NYSE:MED) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NYSE:MED) has 4 ratings reports on Apr 8, 2019 according to StockzIntelligence. On Monday, March 11 the firm has “Buy” rating by DA Davidson given. On Monday, February 25 the firm has “Buy” rating by DA Davidson given. On Thursday, November 8 the stock has “Buy” rating by Sidoti. On Wednesday, February 27 Sidoti maintained Medifast, Inc. (NYSE:MED) rating. Sidoti has “Buy” rating and $216 target.
Medifast, Inc., through its subsidiaries, produces, distributes, and sells weight loss, weight management, healthy living products, and other consumable health and diet products.The company has $1.58 billion market cap. The firm offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, eggs, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape For Life, Flavors of Home, and Essential 1 brands, as well as Dual Fuel, a sports nutrition pilot program.28.87 is the P/E ratio. It also provides meal replacements comprising vitamins and minerals; and hydration products, as well as other nutrients for health purposes.
For more Medifast, Inc. (NYSE:MED) news announced briefly go to: , Seekingalpha.com, Benzinga.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Aurora Cannabis and CanniMed Therapeutics Introduce Product Identification Numbers (PINs) to Medical Cannabis Products – Yahoo News” announced on March 28, 2019, “Novartis prices MS med Mayzent at $88K/year – Seeking Alpha” on March 27, 2019, “Teleflex (NYSE:TFX) Analyst Sees ‘Sustainable Growth Profile’ In Medical Device Manufacturer – Benzinga” with a publish date: March 27, 2019, “Medifast declares $0.75 dividend – Seeking Alpha” and the last “FDA OKs Merck KGaA’s MS med Mavenclad – Seeking Alpha” with publication date: March 30, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.